Doris Rau

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

Ralf Lutterbuese, Tobias Raum, Roman Kischel et al. · Proceedings of the National Academy of Sciences · 2010 · 167 citations

Medicine, Oncology, Pharmacology +17

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

Matthias Friedrich, Tobias Raum, Ralf Lutterbuese et al. · Molecular Cancer Therapeutics · 2012 · 146 citations

Life Sciences, Immunology, Oncology +17

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

Markus Münz, Alexander Murr, Majk Kvesic et al. · Cancer Cell International · 2010 · 122 citations · Full text

Pharmacy, Immunology, Oncology +17

CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis

Michael Mølhøj, Sandrine Crommer, Klaus Brischwein et al. · Molecular Immunology · 2006 · 108 citations

Pharmacy, Immunology, Oncology +16

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Petra Deegen, Oliver S. Thomas, Olivier Nolan-Stevaux et al. · Clinical Cancer Research · 2021 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17